LTP ltr pharma limited

3.45%

30.0¢

Yea it’s super early stage and doesn’t have the team around it...

First 371 Last

Share
Profile

Follow
Bruno81

3,336 Posts.

308

15/04/25

09:42

Post #: 78691857
Share

Originally posted by chuk ↑

After reading their presentation fully, it looks to me that "potential" is the operative word here as well as very early stage and high risk.
They don't seem to have any clinical data, no proof of anything in their presentation, only reference to "ten person observational data".
"¹ Based on formulation design, known compound properties, and a 10-person observational study, where all participants responded within 15 minutes to a 10mg Tadalafil oral film. Comparator data from published averages. Clinical validation pending."
"² Preliminary claims supported by Provisional Patent Application No. 2024902673 (IP Australia), describing a nanoemulsion-based transmucosal delivery platform intended to improve solubility and absorption. Clinical validation pending".
Nothing mentioned of any clinical data showing time to maximum bloodstream concentration like LTP has done which proves time for effectiveness and ruling out any placebo effect.
Nextract's strip is taken orally. Any results from a "10-person observational study" could be showing no more than a placebo effect.
This looks much earlier stage and much more speculative than LTP.

They even state that they have no "proven clinical efficacy" or "or therapeutic equivalence".

"All product-related statements in this presentation reflect formulation design intent, or anecdotal user-reported outcomes from early-stage evaluations. These statements are not intended to imply proven clinical efficacy or therapeutic equivalence to existing products. Clinical trials and regulatory assessments are ongoing or pending, and outcomes are subject to change."

Other than unproven claims of improved speed which could be due to placebo effect in a very small group, is this any different from other oral gel type products already available?
I won't be buying that stock on this information and it certainly doesn't worry me into selling LTP which has the clinical proof.

Expand

Yea it’s super early stage and doesn’t have the team around it like LTP does and is using an already in market drug, prob like LTP was a few years ago.

LTP Price at posting: 35.5¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

First 371 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 30.0¢		Change 0.010(3.45%)		Mkt cap ! $33.58M

Open	High	Low	Value	Volume
29.0¢	30.0¢	28.5¢	$105.7K	362.0K

Buyers (Bids)

No.	Vol.	Price($)
1	17000	29.0¢

Sellers (Offers)

Price($)	Vol.	No.
30.0¢	407	1

View Market Depth

No.	Vol.	Price($)
1	17000	0.290
1	24000	0.285
2	230000	0.280
7	175962	0.275
10	192157	0.270

Price($)	Vol.	No.
0.300	407	1
0.305	9760	1
0.310	31582	3
0.315	9460	1
0.320	36858	4

Last trade - 16.10pm 27/06/2025 (20 minute delay)

LTP (ASX) Chart

Yea it’s super early stage and doesn’t have the team around it...

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Australia’s gas crisis is here – and dying coal plants aren’t helping

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Monash IVF shares cater 25% – Disaster or deep-value play?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Yea it’s super early stage and doesn’t have the team around it...

Top Stories

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Australia’s gas crisis is here – and dying coal plants aren’t helping

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Monash IVF shares cater 25% – Disaster or deep-value play?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News